Skip to main content
. 2019 Oct 25;21(6):108. doi: 10.1208/s12248-019-0378-y

Fig. 2.

Fig. 2

Mean upadacitinib plasma concentration versus time profiles following administration of IR capsule and ER tablet formulations of upadacitinib. ER formulations of upadacitinib contained 10% HPMC (formulation A), 15% HPMC (formulation B), 20% HPMC (formulation C; target formulation), and 35% HPMC (formulation D). Insert: Log-linear scale of mean upadacitinib plasma concentration versus time profiles following administration of IR capsule and ER tablet formulations of upadacitinib